ES2151065T3 - Preparacion enantioselectiva de albuterol opticamente puro. - Google Patents

Preparacion enantioselectiva de albuterol opticamente puro.

Info

Publication number
ES2151065T3
ES2151065T3 ES95919913T ES95919913T ES2151065T3 ES 2151065 T3 ES2151065 T3 ES 2151065T3 ES 95919913 T ES95919913 T ES 95919913T ES 95919913 T ES95919913 T ES 95919913T ES 2151065 T3 ES2151065 T3 ES 2151065T3
Authority
ES
Spain
Prior art keywords
optically pure
acid
amino
enantioselective preparation
pure albuterol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95919913T
Other languages
English (en)
Inventor
Yun Gao
Charles Melvyn Zepp
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma America Inc
Original Assignee
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/247,302 external-priority patent/US5399765A/en
Application filed by Sepracor Inc filed Critical Sepracor Inc
Application granted granted Critical
Publication of ES2151065T3 publication Critical patent/ES2151065T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/10—Separation; Purification; Stabilisation; Use of additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/56—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups
    • C07C215/58—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups with hydroxy groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
    • C07C215/60—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups with hydroxy groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain the chain having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/30—Preparation of optical isomers
    • C07C227/34—Preparation of optical isomers by separation of optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Catalysts (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

LA INVENCION SE REFIERE A UN METODO PARA PRODUCIR ALBUTEROL MEDIANTE LA RESOLUCION DE UNA MEZCLA DE ENANTIOMEROS DE 5-[[]2[[](()1,1-DIMETILETIL())AMINO[]]-1-HIDROXIETIL[]]-2HIDROXIBENZOATO MEDIANTE ACIDO DI-TOLILTARTARICO. LA INVENCION SE REFIERE ADEMAS A UN METODO PARA PRODUCIR ALBUTEROL MEDIANTE LA RESOLUCION DE UNA MEZCLA DE ENANTIOMEROS DE 5-[[]2-[[](()1,1DIMETILETIL())AMINO[]]-1-HIDROXIETIL[]]-2(()FENILMETOXI())BENZOATO METILICO {AL}-[[][[](()1,1DIMETILETIL())AMINO[]]METIL[]]-4-(()FENILMETOXI())-1,3BENCENODIMETANOL UTILIZANDO UN ACIDO QUIRAL COMO ACIDO DITOLILTARTARICO (+/-) O ACIDO DI-BENZOILTARTARICO (+/-).
ES95919913T 1994-05-23 1995-05-23 Preparacion enantioselectiva de albuterol opticamente puro. Expired - Lifetime ES2151065T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/247,302 US5399765A (en) 1994-05-23 1994-05-23 Enantioselective preparation of optically pure albuterol
US08/376,072 US5545745A (en) 1994-05-23 1995-01-20 Enantioselective preparation of optically pure albuterol

Publications (1)

Publication Number Publication Date
ES2151065T3 true ES2151065T3 (es) 2000-12-16

Family

ID=26938588

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95919913T Expired - Lifetime ES2151065T3 (es) 1994-05-23 1995-05-23 Preparacion enantioselectiva de albuterol opticamente puro.

Country Status (11)

Country Link
US (1) US5545745A (es)
EP (1) EP0763010B1 (es)
JP (1) JP3826208B2 (es)
AT (1) ATE195931T1 (es)
AU (1) AU686386B2 (es)
DE (1) DE69518646T2 (es)
DK (1) DK0763010T3 (es)
ES (1) ES2151065T3 (es)
GR (1) GR3034982T3 (es)
PT (1) PT763010E (es)
WO (1) WO1995032178A1 (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136327A (en) 1997-12-01 2000-10-24 Alza Corporation Stereospecific delivery of a drug using electrotransport
WO1999042460A1 (en) * 1998-02-20 1999-08-26 Fine Chemicals Corporation (Proprietary) Limited Process for the production of optically enriched (r)- or (s)-albuterol
ZA994264B (en) 1998-07-01 2000-01-25 Warner Lambert Co Stereoisomers with high affinity for adrenergic receptors.
US7232837B2 (en) * 1999-06-29 2007-06-19 Mcneil-Ppc, Inc. Stereoisomers with high affinity for adrenergic receptors
US6451289B2 (en) * 2000-03-24 2002-09-17 Sepracor Inc. Albuterol formulations
GB0030171D0 (en) * 2000-12-11 2001-01-24 Cipla Ltd Process for preparing isomers of salbutamol
US6596686B2 (en) 2001-03-12 2003-07-22 International Flavors & Fragrances Inc. Use of dihydropyrans as fragrance Material
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
DE60336089D1 (de) * 2002-12-10 2011-03-31 Sunovion Pharmaceuticals Inc Aerosolformulierung umfassend Levalbuterol L-Tartratsalz
WO2004101592A1 (ja) * 2003-05-19 2004-11-25 Taisho Pharmaceutical Co., Ltd. エリスロマイシンａ誘導体の製造方法
US20050020692A1 (en) * 2003-07-24 2005-01-27 Ciofalo Vincent B. Treatment of heaves
NZ547178A (en) * 2003-11-20 2008-06-30 Alteragon Pty Ltd Method of decreasing fat deposits and body weight in mammals and birdsusing the R-isomer of Salbutamol
US7488758B2 (en) * 2004-05-20 2009-02-10 Teva Pharmaceutical Fine Chemicals, S.R.L. Levalbuterol hydrochloride polymorph B
DE102004054054A1 (de) * 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
US7579505B2 (en) * 2004-12-17 2009-08-25 Cipla Limited Crystalline levosalbutamol sulphate and polymorphic forms thereof
EP2311793A1 (en) 2004-12-17 2011-04-20 Cipla Ltd. Crystalline levosalbutamol sulphate (Form II)
EP1832572A1 (en) * 2006-03-08 2007-09-12 Stirling Products Limited Process for the enantiomeric enrichment of salbutamol and salbutamol precursors
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
EP2540725A1 (de) 2006-05-04 2013-01-02 Boehringer Ingelheim International GmbH Polymorphe von 1-((4-Methyl-chinazolin-2-yl)methyl)-3-methyl-7-(2-butin-1-yl)-8-(3-(R)-amino-piperidin-1-yl)xanthin
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
WO2008015689A1 (en) 2006-08-02 2008-02-07 Aarti Healthcare Limited A process for the preparation of optically pure r (-) salbutamol and its pharmaceutically acceptable salts
EP1935872A1 (en) * 2006-12-11 2008-06-25 Stirling Products Limited Process for obtaining the R-enantiomer of salbutamol
WO2009073051A1 (en) * 2007-12-03 2009-06-11 Bridge Pharma, Inc. Use of rr/sr-ractopamine
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
WO2010047717A1 (en) * 2008-10-24 2010-04-29 Biolink Life Sciences, Inc. Stable, water-insoluble r-(+)-alpha-lipoic acid salt useful for the treatment of diabetes mellitus and its co-morbidities
CN102256976A (zh) 2008-12-23 2011-11-23 贝林格尔.英格海姆国际有限公司 有机化合物的盐形式
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
KR20240090632A (ko) 2009-11-27 2024-06-21 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
CN102946875A (zh) 2010-05-05 2013-02-27 贝林格尔.英格海姆国际有限公司 组合疗法
WO2011161161A1 (en) 2010-06-24 2011-12-29 Boehringer Ingelheim International Gmbh Diabetes therapy
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
US8883800B2 (en) 2011-07-15 2014-11-11 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
JP6224084B2 (ja) 2012-05-14 2017-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
JP6218811B2 (ja) 2012-05-14 2017-10-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｓｉｒｓ及び／又は敗血症の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
CA2921385C (en) * 2013-08-15 2021-10-19 Allergan, Inc. (-)-(2r,3s)-2-amino-3-hydroxy-3-pyridin-4-yl-1-pyrrolidin-1-yl-propan-1-one (l)-(+) tartrate salt, its method of production and use
EP3110449B1 (en) 2014-02-28 2023-06-28 Boehringer Ingelheim International GmbH Medical use of a dpp-4 inhibitor
EP3042892A1 (en) 2015-01-09 2016-07-13 Deva Holding Anonim Sirketi Amorphisation of levosalbutamol tartrate
CN109310697A (zh) 2016-06-10 2019-02-05 勃林格殷格翰国际有限公司 利格列汀和二甲双胍的组合
KR102789259B1 (ko) * 2021-11-30 2025-04-02 주식회사 브이에스팜텍 고순도의 1-(1-(2-벤질페녹시)프로판-2-일)-2-메틸피페리딘 단일 이성질체의 제조방법
CN115286521B (zh) * 2022-07-11 2023-11-03 上海医药集团(本溪)北方药业有限公司 一种盐酸左沙丁胺醇的合成方法
CN116693406B (zh) * 2023-06-02 2024-04-19 山东锐顺药业有限公司 一种硫酸沙丁胺醇的制备方法
CN116836069B (zh) * 2023-06-02 2024-01-30 山东锐顺药业有限公司 一种盐酸左沙丁胺醇的制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU648114B2 (en) * 1990-09-11 1994-04-14 Schering Corporation Process for preparing albuterol, acetal, hemi-acetal, and hydrates of arylglyoxal intermediates thereof

Also Published As

Publication number Publication date
US5545745A (en) 1996-08-13
AU2555995A (en) 1995-12-18
DE69518646T2 (de) 2001-04-19
AU686386B2 (en) 1998-02-05
PT763010E (pt) 2000-12-29
ATE195931T1 (de) 2000-09-15
EP0763010B1 (en) 2000-08-30
EP0763010A4 (en) 1997-07-16
JPH10500954A (ja) 1998-01-27
JP3826208B2 (ja) 2006-09-27
DK0763010T3 (da) 2001-01-08
DE69518646D1 (de) 2000-10-05
WO1995032178A1 (en) 1995-11-30
EP0763010A1 (en) 1997-03-19
GR3034982T3 (en) 2001-02-28

Similar Documents

Publication Publication Date Title
ES2151065T3 (es) Preparacion enantioselectiva de albuterol opticamente puro.
DK1082293T3 (da) Formoterol-polymorfer
BR9304185A (pt) Método para a utilização de um selante de fibrina, método para a preparação de ume composição que compreende monõmero de fibrina a partir de fibrinogénio, composição aquosa, composição, kit e suporte sólido
AR070946A2 (es) Proceso para la preparacion de dihidroxiesteres y derivados de los mismos
DE69713374D1 (de) Verfahren zur herstellung von optisch reinen isomeren des formoterols
DK0552041T3 (da) Enzymatiske fremgangsmåder til spaltning af enantiomerblandinger af forbindelser, der er nyttige som mellemprodukter ved fr
CY1110919T1 (el) Μεθοδος για τον ενζυματικο διαχωρισμο εναντιομερων της 3(r)- kai 3(s)-υδροξυ-1-μεθυλο-4-(2,4,6-τριμεθοξυφαινυλο)-1,2,3,6-τετραϋδρο-πυριδινης ή των εστερων καρβοξυλικου οξεος αυτης.
EP0956033A4 (en) TOTAL SYNTHESIS OF THE AMINO HIP ANALOG OF DIDEMNIN A
BR0111472A (pt) Processo para a preparação de um composto, composto, e, forma polimórfica de um composto
CO4700282A1 (es) Compuestos
NO20016151L (no) Fremstilling av substituerte piperidin-4-oner
AU1289600A (en) Process for racemization
HU903056D0 (en) Method for producing optically active ceramide type compounds
BR0004965A (pt) Processo para preparação de compostos de cromano esterificados
NO994083L (no) Selektiv epoksideringsmetode for fremstilling av farmasöytiske forbindelser
EP0353538A3 (en) Process for the preparation of intermediates for the synthesis of diltiazem
CA2190577A1 (en) Enantioselective preparation of optically pure albuterol
EA200000127A1 (ru) Способ получения аминопроизводных алкилоксифуранона, получаемые этим способом соединения и применение этих соединений
DE69903320D1 (de) Verfahren zur herstellung von r-(-)-carnitin
RU2004106530A (ru) Защищенные 3, 5-дигидрокси-2, 2-диметилвалероамиды для синтеза эпотилонов и их производных, способ их получения и их применение
BR0008586A (pt) Processo de preparação de aminoácidos quirais e processo de preparação de compostos a partir destes
BR9908511A (pt) Processo para a preparação de um composto, e, composto
DE69717653D1 (de) Verfahren zur herstellung von glycidylethern
EP0385423A3 (de) Verfahren zur Herstellung der optischen Isomeren von 1,4-Dihydro-5-isopropoxy-2-methyl-4-(2-trifluormethylphenyl)-1,6-naphthyridin-3-carbonsäure-ethyl-ester und 1,4-Dihydro-5-isopropoxy-2-methyl-4-(2-trifluormethylphenyl)-1,6-naphthyridin-3-carbonsäure- 2-(N-methyl-N-phenylmethylamino)ethyl ester
JPS5528914A (en) Preparation of optically active benzyl alcohol derivative

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 763010

Country of ref document: ES